XpresCheck

XpresCheck specializes in infectious disease monitoring, primarily through COVID-19 testing and comprehensive biosurveillance initiatives conducted at U.S. airports. The company tests over 6,000 travelers weekly, processing samples from individuals arriving from various international locations. Their operational scope includes the detection of emerging pathogens and variants, contributing significantly to public health safety protocols within transportation hubs. This focus on real-time monitoring and rapid response positions XpresCheck as a key player in pandemic preparedness and ongoing health security.

Utilizing advanced diagnostic methods such as nasal swabs and innovative wastewater testing, XpresCheck actively identifies COVID-19 variants and other infectious agents. Their work is crucial for public health surveillance, often in collaboration with governmental bodies like the CDC, to track and mitigate potential outbreaks. The operational efficiency and scientific rigor behind their testing procedures are managed by a dedicated team. Meet XpresCheck's team to understand the expertise driving these critical public health services. The company's commitment extends to ensuring traveler safety and preventing the spread of diseases across borders.

With a revenue of $68.9M and employing between 500-1,000 individuals, XpresCheck operates testing facilities across multiple major U.S. airports. Their strategic placement within these high-traffic areas allows for immediate sample collection and analysis, directly supporting national health objectives. The company's services are designed to provide actionable data for public health agencies, enhancing their ability to respond effectively to health threats. XpresCheck's model integrates public health needs with logistical capabilities in critical infrastructure.